13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001913464
Total reported value
$118.0M
$118.0M
230 檔
14.1%
During the Q3 2024 filing period, AlphaCentric Advisors LLC (CIK: 0001913464) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $118.0M across 230 reported positions.
AlphaCentric Advisors LLC executed strategic sector rebalancing during Q3 2024, establishing 14 new positions while fully exiting 12 holdings and trimming 13 positions.
Showing top 200 holdings (of 230 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RITM | Rithm Capital CORP | Stock-Real Estate | 3.21% | — | — | |
| 2 | HRMY | Harmony Biosciences Holdings | Stock-Other | 2.88% | — | -20.49% | |
| 3 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 2.32% | — | — | |
| 4 | MRK | Merck & Co. Inc. | Stock-Healthcare | 2.03% | — | — | |
| 5 | EFC | Ellington Financial Inc | Stock-Other | 1.93% | — | — | |
| 6 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.93% | +0.13% | +221.43% | |
| 7 | MTG | Mgic Investment CORP | Stock-Financials | 1.89% | — | -13.11% | |
| 8 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.81% | +0.11% | -37.93% | |
| 9 | INDV | Indivior Pharmaceuticals, Inc. | Stock-Other | 1.76% | — | — | |
| 10 | DX | Dynex Capital Inc | Stock-Other | 1.72% | — | — | |
| 11 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.70% | — | +96.97% | |
| 12 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.67% | — | +140.00% | |
| 13 | DVAX | Dynavax Technologies CORP | Stock-Other | 1.67% | — | +55.00% | |
| 14 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.66% | — | -56.90% | |
| 15 | RWT | Redwood Trust Inc | Stock-Other | 1.66% | — | — | |
| 16 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.63% | — | +1.23% | |
| 17 | MFA | Mfa Financial Inc | Stock-Other | 1.59% | — | — | |
| 18 | ATEC | Alphatec Holdings Inc | Stock-Other | 1.53% | — | — | |
| 19 | EXK | Exact Sciences CORP | Stock-Materials | 1.52% | — | — | |
| 20 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 1.52% | +1.16% | NEW | |
| 21 | QQQM | Invesco Nasdaq 100 ETF | ETF-Tech | 1.52% | +1.16% | NEW | |
| 22 | RPRX | Royalty Pharma plc | Stock-Healthcare | 1.42% | — | +12.50% | |
| 23 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 1.30% | — | -29.69% | |
| 24 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 1.28% | +0.07% | +40.91% | |
| 25 | MITT | Tpg Mortgage Investment Trus | Stock-Other | 1.17% | — | — | |
| 26 | ACT | Enact Holdings Inc | Stock-Other | 1.14% | — | — | |
| 27 | ELS | Equity Lifestyle Properties | Stock-Real Estate | 1.09% | — | — | |
| 28 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 1.09% | — | — | |
| 29 | AMPH | Amphastar Pharmaceuticals In | Stock-Other | 1.08% | — | +20.00% | |
| 30 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.07% | — | -10.71% | |
| 31 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 1.06% | — | — | |
| 32 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.02% | — | — | |
| 33 | ADAM | Adamas Trust Inc | Stock-Other | 0.95% | — | — | |
| 34 | RVNCEUR | Revance Therapeutics Inc | Stock-Other | 0.95% | — | — | |
| 35 | ONC | Beone Medicines Ltd-adr | Stock-Other | 0.92% | — | -63.33% | |
| 36 | STXS | Stereotaxis Inc | Stock-Other | 0.91% | -0.23% | — | |
| 37 | ENOV | Enovis CORP | Stock-Other | 0.88% | — | +37.50% | |
| 38 | TWO 6.25 01-15-26Bond | Two Harbors Inv CORP | Bond | 0.88% | — | — | |
| 39 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.86% | +0.13% | +13.64% | |
| 40 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.85% | — | — | |
| 41 | TAK | Takeda Pharmaceutic-sp Adr | Stock-Healthcare | 0.85% | — | — | |
| 42 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.84% | — | — | |
| 43 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.79% | — | -2.44% | |
| 44 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.76% | — | -36.84% | |
| 45 | PFE | Pfizer Inc | Stock-Healthcare | 0.75% | — | -75.00% | |
| 46 | SNY | Sanofi-adr | Stock-Healthcare | 0.75% | -0.16% | — | |
| 47 | IMVT | Immunovant Inc | Stock-Other | 0.74% | — | -4.11% | |
| 48 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.73% | — | — | |
| 49 | PMT 5.5 11-01-24Bond | Pennymac CORP | Bond | 0.71% | — | — | |
| 50 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.70% | +0.26% | -30.00% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MRK | Merck & Co. Inc. | +2% | NEW | New buy |
| 2 | INDV | Indivior Pharmaceuticals, Inc. | +1.8% | NEW | New buy |
| 3 | ATEC | Alphatec Holdings Inc | +1.5% | NEW | New buy |
| 4 | NBIX | Neurocrine Biosciences Inc | +1.2% | +221.43% | Add |
| 5 | APLSUSD | Apellis Pharmaceuticals Inc | +1% | NEW | New buy |
| 6 | TAK | Takeda Pharmaceutic-sp Adr | +0.9% | NEW | New buy |
| 7 | SRPT | Sarepta Therapeutics Inc | +0.8% | +140.00% | Add |
| 8 | LNTH | Lantheus Holdings Inc | +0.7% | NEW | New buy |
| 9 | BMRN | Biomarin Pharmaceutical Inc | +0.7% | +96.97% | Add |
| 10 | DVAX | Dynavax Technologies CORP | +0.6% | +55.00% | Add |
| 11 | EXK | Exact Sciences CORP | +0.6% | — | Unchanged |
| 12 | PEN | Penumbra Inc | +0.6% | NEW | New buy |
| 13 | NUVL | Nuvalent Inc-a | +0.5% | NEW | New buy |
| 14 | MLTX | Moonlake Immunotherapeutics | +0.5% | NEW | New buy |
| 15 | CYTK | Cytokinetics Inc | +0.5% | NEW | New buy |
| 16 | RVNCEUR | Revance Therapeutics Inc | +0.5% | — | Unchanged |
| 17 | VRNA | Verona Pharma PLC - Adr | +0.5% | -10.71% | Trim |
| 18 | CGNX | Cognex CORP | +0.5% | NEW | New buy |
| 19 | ROK | Rockwell Automation Inc | +0.5% | NEW | New buy |
| 20 | JAZZ | Jazz Pharmaceuticals plc | +0.4% | +40.91% | Add |
| 21 | APGE | Apogee Therapeutics Inc | +0.4% | NEW | New buy |
| 22 | QQQM | Invesco Nasdaq 100 ETF | +0.4% | +28.60% | Add |
| 23 | QQQ | Invesco Qqq Trust Series 1 | +0.4% | +28.40% | Add |
| 24 | KROS | Keros Therapeutics Inc | +0.4% | NEW | New buy |
| 25 | AMPH | Amphastar Pharmaceuticals In | +0.3% | +20.00% | Add |
| 26 | LKFT | Lakefront Biotherapeutic-adr | +0.3% | — | Unchanged |
| 27 | AUPH | Aurinia Pharmaceuticals Inc | -0.3% | EXIT | Sold out |
| 28 | IWD | Ishares Russell 1000 Value E | -0.4% | EXIT | Sold out |
| 29 | RPV | Invesco S&p 500 Pure Value E | -0.4% | EXIT | Sold out |
| 30 | RWT 7.75 06-15-27Bond | Redwood Trust Inc | -0.4% | EXIT | Sold out |
| 31 | CABA | Cabaletta Bio Inc | -0.4% | EXIT | Sold out |
| 32 | VKTX | Viking Therapeutics Inc | -0.5% | -78.79% | Trim |
| 33 | ARGX | Argenx Se - Adr | -0.5% | -37.93% | Trim |
| 34 | SNPS | Synopsys Inc | -0.5% | -50.00% | Trim |
| 35 | CLDX | Celldex Therapeutics Inc | -0.5% | -36.84% | Trim |
| 36 | NARIUSD | Inari Medical Inc | -0.5% | EXIT | Sold out |
| 37 | TRML | Tourmaline Bio Inc | -0.6% | -92.67% | Trim |
| 38 | ONC | Beone Medicines Ltd-adr | -0.7% | -63.33% | Trim |
| 39 | MDT | Medtronic plc | -0.7% | -71.43% | Trim |
| 40 | RWT 5.75 10-01-25Bond | Rwt Holdings Inc | -0.7% | EXIT | Sold out |
| 41 | ACAD | Acadia Pharmaceuticals Inc | -0.7% | -60.00% | Trim |
| 42 | AVBP | Arrivent Biopharma Inc | -0.9% | -82.56% | Trim |
| 43 | CHRS | Coherus Oncology Inc | -1% | -67.00% | Trim |
| 44 | CERE1EUR | Cerevel Therapeutics Holding | -1.3% | EXIT | Sold out |
| 45 | DCGO | Docgo Inc | -1.5% | EXIT | Sold out |
| 46 | QURE | uniQure N.V. | -1.5% | EXIT | Sold out |
| 47 | UTHR | United Therapeutics CORP | -1.7% | -56.90% | Trim |
| 48 | PFE | Pfizer Inc | -2.1% | -75.00% | Trim |
| 49 | PCRX | Pacira Biosciences Inc | -2.5% | EXIT | Sold out |
| 50 | BCRX | Biocryst Pharmaceuticals Inc | -3.1% | EXIT | Sold out |
According to official SEC Form 13F filings, AlphaCentric Advisors LLC reported a total U.S. public equity portfolio value of $118.0M across 230 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including RITM, HRMY, LKFT) accounted for 14.1% of total reported equity market value during Q3 2024.
Top New Position Initiated
MRK
市值: $2.7M
Top Position Liquidated / Trimmed
BCRX
前期市值: $4.2M
During Q3 2024, AlphaCentric Advisors LLC's top holdings by market value included RITM (3.2%)、HRMY (2.9%)、LKFT (2.3%). The largest single position, RITM, represented 3.2% of total portfolio value.
In Q3 2024, AlphaCentric Advisors LLC made 47 total portfolio adjustments, initiating 14 new buys, adding to 8 positions, trimming 13 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.